Acura Pharma shares rise after generic drug deal

Posted On 10 Oct 2013
By :

Shares of Acura Pharmaceuticals Inc. jumped Thursday, a day after the drug developer said it reached a settlement with two generic drugmakers over future sales of new versions of Pfizer Inc.’s painkiller Oxecta.

THE SPARK: Acura, based in Palatine, Ill., said Par Pharmaceuticals will be able to launch a generic form of Oxecta in the United States in 2022, or possibly sooner under certain circumstances. But Par will have to pay Acura royalties of between 10 percent and 15 percent of the net profits from the generic.

Par will have six months of marketing exclusivity for its generic. Then another rival, Impax Laboratories, can launch its version, subject to regulatory approval.


Read the source article at Yahoo! News

About the Author

Leave a Reply